This educational video series describes the clinical presentation of Lambert-Eaton myasthenic syndrome (LEMS), the challenges of diagnosis, and the role that FIRDAPSE® can play in treatment. This content was featured in a presentation delivered at the 2019 Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine.
This video describes disorders of the neuromuscular junction, mechanisms of disease, and the pathophysiology, classification, and clinical presentation of LEMS.
Presented by Perry B. Shieh, MD, PhD
Department of Neurology
David Geffen School of Medicine at UCLA
This video presents diagnostic approaches for LEMS, common misdiagnoses, and the expected progression of disease.
Presented by Perry B. Shieh, MD, PhD
Department of Neurology
David Geffen School of Medicine at UCLA
This video provides a clinical overview of FIRDAPSE, including its MOA and the efficacy and safety results from two Phase 3 clinical trials.
Presented by Perry B. Shieh, MD, PhD
Department of Neurology
David Geffen School of Medicine at UCLA
This program and its materials have been sponsored by Catalyst Pharmaceuticals. The speaker has been compensated by Catalyst Pharmaceuticals to provide this presentation. This presentation is consistent with all applicable US Food and Drug Administration (FDA) requirements and the approved product labeling for FIRDAPSE. This program is not intended for continuing education credit for healthcare professionals. Any expenditures in relation to this event may be reported as required by state and federal spend-reporting requirements.
indications and usage:
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
CONTRAINDICATIONS
FIRDAPSE is contraindicated in patients with:
WARNINGS AND PRECAUTIONS
Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment.
Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.
ADVERSE REACTIONS
The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.
Please see full Prescribing Information for additional Important Safety Information.
To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
indications and usage:
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
CONTRAINDICATIONS
FIRDAPSE is contraindicated in patients with:
WARNINGS AND PRECAUTIONS
Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment.
Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.
ADVERSE REACTIONS
The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.
Please see full Prescribing Information for additional Important Safety Information.
To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
